|Other names||CVL-751; PF-6649751; PF-06649751|
|Chemical and physical data|
|Molar mass||391.350 g·mol−1|
|3D model (JSmol)|
Tavapadon (developmental code names CVL-751, PF-6649751, PF-06649751) is a dopamine receptor agonist which is under development by Pfizer and Cerevel Therapeutics for the treatment of Parkinson's disease. It acts as a selective partial agonist of the dopamine D1 (Ki = 8.54 nM) and D5 receptors. It also shows biased agonism for Gs-coupled signaling. As of July 2021, tavapadon is in phase 3 clinical trials for Parkinson's disease.